A COMPARATIVE EVALUATION OF THE EFFICACY OF TRIPLE DRUG THERAPY WITH DUAL DRUG THERAPY IN COPD PATIENTS
DOI:
https://doi.org/10.22159/ijpps.2018v10i4.24529Keywords:
Chronic obstructive pulmonary disease (COPD), Inhaled corticosteroids, Nil, Long-acting muscuranic antagonist, SpirometryAbstract
Objective: The present study was conducted with the objective of analyzing the efficacy of triple-drug combination therapy (formoterol, ciclesonide, tiotropium) by comparing it with double drug combination therapy (formoterol, budesonide).
Methods: A prospective observational study was conducted. Sixty patients were enrolled, and divided into two groups of thirty each; one group was treated with the double-drug and the other with a triple drug combination. FEV1 and FVC pre-and post-treatment in either group were assessed spirometrically. Score ranges of 0-10, 11-20 and 21-30 were allotted to mild, moderate and severe categories and results were analyzed statistically.
Results: Of the 60 patients recruited, 61-70 y olds constituted the majority (35%) of the population. Males (63.3%) were more in number compared to females (36.6%). Twenty-three of thirty-eight men smoked (60.5%); there were no female smokers. Common symptoms included cough (93.3%), dyspnoea (85%), fever (45%) and haemoptysis (15%). Hypertension accounted for 70% of patient comorbidities, followed by diabetes (60%) and cardiovascular diseases (40%). Three months after treatment with triple therapy, a significant increase in the differences of means of both FEV1 (14.27) and FVC (14.90) values was observed. Further analysis based on score ranges demonstrated that triple therapy administration markedly reduced the number of patients suffering from severe COPD.
Conclusion: Our comparative analysis indicated that triple therapy was more effective in improving lung function, enhancing patients' quality of life (evidenced from score ranges) thereby reducing mortality. While much is known about the greater effectiveness of triple over dual therapy, researchers to formulate the most effective triple therapy are in progress.
Downloads
References
Petty TL. COPD in perspective. Chest 2002;121:116S–20S.
Fishman AP. One hundred years of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:941–8.
Harris HW. Chronic bronchitis, emphysema and asthma. Am J Public Health Nations Health 1963;53(Suppl 3):7-15.
Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the medical research council by their committee on the aetiology of chronic bronchitis. Lancet 1965;1:775-9.
Global Initiative for chronic obstructive lung disease: pocket guide to COPD diagnosis, management and prevention; 2017.
Pride NB. Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax 2001;56(Suppl 2):ii7–ii10.
Burki NK. Chronic airway obstruction. J Fam Pract 1980;11:301-5.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5:020415.
World Health Organization. Causes of COPD. Available from: http://www.who. int/respiratory/copd/causes/en/ [Last accessed on 30 Nov 2017]
Oliver P, Buno A, Alvarez-Sala R. Arterial blood gas analyses in chronic obstructive pulmonary disease: in the clinical laboratory or as point-of-care testing? Austin J Pulm Respir Med 2015;2:1024.
Wells BG, Dipiro JT, Schwinghammer TL, Dipro CV. Pharmacotherapy handbook. 9th ed. McGraw-Hill Education; 2015.
Salvi S, Agrawal A. India needs a national COPD prevention and control programme. J Assoc Physicians India 2012;60 Suppl:5-7.
Cazzola M, Matera MG. Triple combinations in chronic obstructive pulmonary disease-Is three better than two? Expert Opin Pharmacother 2014;15:2475-8.
Afonso ASM, Verhamme KMC, Sturkenboom MCJM, Brusselle GGO. COPD in the general population: prevalence, incidence and survival. Respir Med 2011;105:1872-84.
Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013;8:e63285.
Anecchino C, Rossi E, Fanizza C, Rosa MD, Tognoni G, Romero M. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis 2007;2:567–74.
Van Durme YMTA, Verhamme KMC, Stijnen T, Van Rooij FJA, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the rotterdam study. Chest 2009;135:368-77.
Mohan H. Textbook of pathology. 6th ed. Jaypee Brothers Medical Publishers (P) Ltd; 2010.
Varughese JD, Jayakumari S. A prospective observational study on health-related quality of life in chronic obstructive pulmonary disease patients based on severity. Asian J Pharm Clin Res 2017;10:244-7.
Camp PG, O’Donnell DE, Postma DS. Chronic obstructive pulmonary disease in men and women: myths and reality. Proc Am Thorac Soc 2009:6:535-8.
Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:305-14.
Imaizumi Y, Eguchi K, Kario K. Lung disease and hypertension. Pulse (Basel) 2014;2:103-12.
Samanth J, Padmakur R, Mohapatra A, Krishnananda N, Patil N, Karthik RN. Use of tissue doppler imaging to detect right ventricular myocardial dysfunction in patients with chronic obstructive pulmonary disease. Asian J Pharm Clin Res 2017;10:118-24.
Glaser S, Krüger S, Merkel M, Bramlage P, Herth FJ. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration 2015;89:253-64.
Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of ‘‘triple’’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592–8.
Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20:556-61.
Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-73.
Barnes PJ. Triple inhalers for obstructive airways disease: will they be useful? Expert Rev Respir Med 2011;5:297-300.
Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
Chapman KR, Beeh KM, Beier J, Bateman ED, D’Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW 5 study. BMC Pulm Med 2014;14:4.
Published
How to Cite
Issue
Section
